SOLVConferences/Events
Solventum to Participate in the 2026 Jefferies Healthcare Conference
Solventum to Participate in the 2026 Jefferies Healthcare Conference
Read more →SOLVGeneral
Solventum Foundation and America's ToothFairy Launch National Effort to Expand Access to Preventive Dental Care
Solventum Foundation and America's ToothFairy Launch National Effort to Expand Access to Preventive Dental Care
Read more →SOLVConferences/Events
Solventum to Participate in the 2026 BofA Securities Health Care Conference
Solventum (NYSE: SOLV) will participate in a fireside chat at the BofA Securities Health Care Conference on May 13, 2026. The event will take place at 10:00 a.m. PDT in Las Vegas, NV. The company aims to highlight its innovative healthcare solutions and engage with stakeholders during this prominent event.
Read more →SOLVGeneral
Solventum Reports First Quarter 2026 Financial Results
Solventum reported its first quarter financial results for 2026, showing a 3.0% decrease in reported sales but a 2.1% increase in organic sales. The adjusted diluted earnings per share rose by 10.6%, and the company affirmed its full-year guidance for organic sales growth. However, both operating cash flow and free cash flow were negative, reflecting ongoing challenges.
Read more →SOLVGeneral
Solventum to Report First Quarter Fiscal 2026 Earnings on May 5, 2026
Solventum (NYSE: SOLV) will announce its first quarter fiscal 2026 earnings on May 5, 2026, after market close. A webcast will follow the earnings release for management to discuss the results and other relevant information. The company aims to enhance healthcare through innovative solutions.
Read more →SOLVConferences/Events
Solventum to Participate in the 2026 KeyBanc Healthcare Forum
Solventum to Participate in the 2026 KeyBanc Healthcare Forum
Read more →SOLVGeneral
Solventum Reports Fourth Quarter 2025 Financial Results and Introduces 2026 Full-Year Guidance R eported sales decreased 3.7% organic sales increased 3.5% Introduces full-year 2026 organic sales growth, adjusted EPS and
Solventum reported its fourth quarter 2025 financial results, revealing a 3.7% decrease in reported sales despite a 3.5% increase in organic sales. The net income for the year rose significantly by 224.8%, and the company provided guidance for 2026, projecting organic sales growth of 2.0% to 3.0%. However, challenges persist, with a notable decline in free cash flow of 64.1% in the fourth quarter. The CEO emphasized the company's ongoing transformation and commitment to achieving long-term goals.
Read more →SOLVGeneral
Solventum to Report Fourth Quarter and Full Year Fiscal 2025 Earnings on February 26, 2026
Solventum to Report Fourth Quarter and Full Year Fiscal 2025 Earnings on February 26, 2026
Read more →SOLVGeneral
Solventum Completes Acquisition of Acera Surgical
Solventum has finalized its acquisition of Acera Surgical, a company specializing in engineered materials for regenerative wound care. This acquisition, valued at $725 million with additional contingent payments, aims to enhance Solventum's wound care offerings. The CEO emphasized the strategic importance of this move in their transformation plan, which is expected to benefit patients and shareholders alike.
Read more →SOLVGeneral
Global Expert Panel Publishes New Recommendations on Advanced Use of Closed Incision Negative Pressure Therapy
Global Expert Panel Publishes New Recommendations on Advanced Use of Closed Incision Negative Pressure Therapy
Read more →SOLVGeneral
Solventum Earns Diamond Level HIRC Resiliency Badge, Demonstrating Best-In-Class Supply Chain Strength
Solventum Earns Diamond Level HIRC Resiliency Badge, Demonstrating Best-In-Class Supply Chain Strength
Read more →SOLVConferences/Events
Solventum to Participate in the 2025 Piper Sandler Healthcare Conference
Solventum to Participate in the 2025 Piper Sandler Healthcare Conference
Read more →SOLVGeneral
Solventum Announces $1 Billion Share Repurchase Program
Solventum Announces $1 Billion Share Repurchase Program
Read more →SOLVGeneral
Solventum Announces Agreement to Acquire Acera Surgical
Solventum Announces Agreement to Acquire Acera Surgical
Read more →SOLVGeneral
Solventum Reports Third Quarter 2025 Financial Results R eported sales increased 0.7% organic sales increased 2.7% Expects full year organic sales growth to be at the high end of +2.0% to +3.0% range Increases full year
Solventum has reported its third quarter financial results for 2025, showing a 0.7% increase in total sales and a 2.7% rise in organic sales. The company has raised its full-year guidance for organic sales growth and adjusted earnings per share outlook, reflecting positive momentum across all business segments. However, challenges persist with a significant decline in operating cash flow and negative free cash flow, alongside a decrease in operating income margins attributed to tariffs and costs related to growth initiatives. The new 'Transform for the Future' initiative is expected to enhance operational efficiency and generate considerable cost savings.
Read more →SOLVConferences/Events
Solventum to Participate in the 2025 Stifel Healthcare Conference
Solventum to Participate in the 2025 Stifel Healthcare Conference
Read more →SOLVGeneral
Solventum Appoints Heather Knight as Chief Commercial Officer
Solventum Appoints Heather Knight as Chief Commercial Officer
Read more →SOLVGeneral
Solventum to Report Third Quarter Fiscal 2025 Earnings on November 6, 2025
Solventum to Report Third Quarter Fiscal 2025 Earnings on November 6, 2025
Read more →SOLVGeneral
Solventum Announces Pricing of its Upsized $2 Billion Note Tender Offers
Solventum has announced the pricing of its up to $2 billion note tender offers, aimed at repurchasing specific series of its outstanding notes. These offers reflect an increase in the Aggregate Cap and are designed to enhance the company's financial stability. The lead dealer managers for this initiative include major financial institutions like J.P. Morgan and Goldman Sachs. While the tender offer presents an opportunity for note holders, it excludes certain series, which may affect some investors.
Read more →SOLVGeneral
Solventum Announces Early Tender Results and Upsizing of its Note Tender Offers
Solventum Announces Early Tender Results and Upsizing of its Note Tender Offers
Read more →SOLVGeneral
Solventum Completes Sale of its Purification Filtration Business to Thermo Fisher Scientific Inc. Accelerates Solventum's business transformation to deliver long-term shareholder value Net proceeds will be used primarily
Solventum has successfully finalized the sale of its Purification Filtration business to Thermo Fisher Scientific for $4.0 billion. This transaction is seen as a significant step in Solventum's transformation strategy, intended to reduce debt and improve its capital allocation. The company has updated its financial guidance for 2025, reflecting positive adjustments in adjusted earnings per share and an anticipated reduction in net interest expenses. Following this sale, Solventum will continue providing transitional services to Thermo Fisher.
Read more →SOLVConferences/Events
Solventum to Participate in Upcoming Investor Conferences
Solventum to Participate in Upcoming Investor Conferences
Read more →SOLVGeneral
Solventum Announces $1.75 Billion Note Tender Offers
Solventum Corporation has announced a $1.75 billion tender offer to purchase outstanding notes. This initiative aims to manage its debt effectively and provide liquidity to noteholders. The offers are subject to specific conditions outlined in the offer to purchase dated August 22, 2025. With an early tender date set for September 5, 2025, the tender process indicates a proactive approach by Solventum to optimize its financial strategy.
Read more →SOLVGeneral
Solventum Announces Pricing of Secondary Offering of Common Stock
Solventum Corporation has announced the pricing details for a secondary offering of 8,800,000 shares of its common stock. The offering is expected to generate gross proceeds of approximately $648 million for the selling shareholder, 3M Company, without benefiting Solventum. The offering is scheduled to close on or about August 15, 2025, pending customary closing conditions and will be conducted under Solventum's SEC registration statement. As this offering involves the sale of shares solely by 3M Company, Solventum will not receive any of the proceeds from the transaction.
Read more →SOLVGeneral
Solventum Corporation Unaudited Pro Forma Condensed Consolidated Financial Statements On
Solventum Corporation has entered into a Transaction Agreement to sell its purification and filtration business to Thermo Fisher Scientific for approximately $4.0 billion, following an amendment that excludes the company's water filtration segment. The company has prepared unaudited pro forma condensed consolidated financial statements that project the financial position as if the transaction had been completed prior to June 30, 2025. This demonstrates their current financial health and anticipated operational adjustments post-sale.
Read more →SOLVGeneral
Solventum Announces Launch of Secondary Offering of Common Stock
Solventum Announces Launch of Secondary Offering of Common Stock
Read more →SOLVGeneral
Solventum Reports Second Quarter 2025 Financial Results Reported sales increased 3.9% organic sales increased 2.8% Increases full year organic sales growth outlook to +2.0% to +3.0% Increases full year earnings per share
Solventum reported its financial results for Q2 2025, highlighting a 3.9% increase in sales and improved organic sales growth forecasts. The company raised its full-year guidance for both organic sales and earnings per share, reflecting confidence in its transformation strategy. Despite these positive developments, the company faced challenges with declining operating margins and significant drops in net income and free cash flow compared to the previous year.
Read more →SOLVGeneral
Solventum to Report Second Quarter Fiscal 2025 Earnings on August 7, 2025
Solventum to Report Second Quarter Fiscal 2025 Earnings on August 7, 2025
Read more →SOLVGeneral
Solventum Named a Best Company to Work for by U.S. News & World Report
Solventum Named a Best Company to Work for by U.S. News & World Report
Read more →SOLVConferences/Events
Solventum to Participate in the 2025 Goldman Sachs Health Care Conference
Solventum to Participate in the 2025 Goldman Sachs Health Care Conference
Read more →SOLVGeneral
Solventum Reports First Quarter 2025 Financial Results Reported sales increased 2.6% organic sales increased 4.3% Increases full year organic sales growth outlook by 50 bps to +1.5% to +2.5%
Solventum reported its first quarter 2025 financial results, showcasing a 2.6% increase in reported sales, with organic sales rising by 4.3%. The company also updated its full-year 2025 organic sales growth outlook, increasing it to between 1.5% and 2.5%. However, the net income saw a significant decline of 42.2%, and diluted earnings per share fell by 43.1% compared to the previous year. Operating cash flow also decreased sharply, indicating challenges despite the revenue growth.
Read more →SOLVConferences/Events
Solventum to Participate in the 2025 BofA Securities Health Care Conference
Solventum to Participate in the 2025 BofA Securities Health Care Conference
Read more →SOLVGeneral
Solventum to Report First Quarter Fiscal 2025 Earnings on May 8, 2025
Solventum to Report First Quarter Fiscal 2025 Earnings on May 8, 2025
Read more →SOLVGeneral
Solventum partners with SprintRay to disrupt the digital dentistry market with high-quality, permanent same-day restorations
Solventum partners with SprintRay to disrupt the digital dentistry market with high-quality, permanent same-day restorations
Read more →SOLVConferences/Events
Solventum to Present Value Creation Formula and Long-Range Plan at 2025 Investor Day
Solventum to Present Value Creation Formula and Long-Range Plan at 2025 Investor Day
Read more →SOLVGeneral
Solventum Launches Attest™ eBowie-Dick Test System Revolutionizing Sterilization Assurance
Solventum Launches Attest™ eBowie-Dick Test System Revolutionizing Sterilization Assurance
Read more →SOLVGeneral
Solventum Reports Fourth Quarter 2024 Financial Results and Introduces 2025 Full-Year Guidance Reported sales increased 1.9% to $2.074 billion organic sales increased 2.3% GAAP diluted Earnings Per Share (EPS) of $0.17 a
Solventum reported its fourth quarter financial results for 2024, showcasing a 1.9% increase in sales to $2.074 billion and a 2.3% rise in organic sales. Despite a decline in operating income margins, the company expressed confidence in its ongoing transformation plan and provided optimistic guidance for 2025, expecting organic sales growth between 1.0%-2.0% and an adjusted EPS of $5.45 to $5.65. The performance reflects positive trends in MedSurg and Dental Solutions segments, while the company is mindful of operational and market risks.
Read more →SOLVConferences/Events
Solventum to Host Investor Day on Thursday, March 20, 2025, in New York City
Solventum to Host Investor Day on Thursday, March 20, 2025, in New York City
Read more →SOLVGeneral
▲ +9.5%on this newsshared move
Solventum Announces Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B
Solventum Announces Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B
Read more →SOLVGeneral
Solventum Fluency for Imaging clinches top spot again: Ranked #1 Best in KLAS for Speech Recognition: Front-end Imaging
Solventum Fluency for Imaging clinches top spot again: Ranked #1 Best in KLAS for Speech Recognition: Front-end Imaging
Read more →SOLVGeneral
Solventum to Report Fourth Quarter and Full Year Fiscal 2024 Earnings on February 27, 2025
Solventum to Report Fourth Quarter and Full Year Fiscal 2024 Earnings on February 27, 2025
Read more →SOLVConferences/Events
Solventum to Participate in the Piper Sandler Healthcare Conference
Solventum to Participate in the Piper Sandler Healthcare Conference
Read more →SOLVGeneral
Solventum Launches First 3D Printed Aligner Attachments to Revolutionize Aligner Treatment
Solventum Launches First 3D Printed Aligner Attachments to Revolutionize Aligner Treatment
Read more →SOLVGeneral
Solventum Reports Third Quarter 2024 Financial Results and Raises Full-Year Guidance Reported sales increased 0.4% to $2.082 billion organic sales increased 0.3% GAAP Earnings Per Share (EPS) of $0.70 adjusted EPS 1 of $
Solventum has reported its financial results for the third quarter of 2024, indicating a slight increase in sales of 0.4%, amounting to $2.082 billion. The company has raised its full-year guidance for organic sales growth, adjusted earnings per share, and free cash flow based on its recent performance. Additionally, the results reflect operational challenges as both GAAP and adjusted operating income margins have declined due to increased operational expenses and lower gross margins.
Read more →SOLVConferences/Events
Solventum to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024
Solventum to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024
Read more →SOLVGeneral
Solventum Announces Commitment to 100% Renewable Electricity by 2030
Solventum Announces Commitment to 100% Renewable Electricity by 2030
Read more →SOLVGeneral
Solventum Names Surgeon and Diagnostics Pioneer Dr. Ryan Egeland as Chief Medical Officer
Solventum Names Surgeon and Diagnostics Pioneer Dr. Ryan Egeland as Chief Medical Officer
Read more →SOLVGeneral
Solventum Launches All-In-One, Extended-Wear Wound Dressing for V.A.C.® Therapy
Solventum Launches All-In-One, Extended-Wear Wound Dressing for V.A.C.® Therapy
Read more →SOLVGeneral
Solventum autonomous coding listed in Epic Toolbox
Solventum autonomous coding listed in Epic Toolbox
Read more →SOLVGeneral
Solventum Reports Second Quarter 2024 Financial Results and Raises Full-Year Guidance Separation activities and business continuity on track Reported sales increased 0.2% to $2.081 billion organic sales increased 1.3% GA
Solventum reported its financial results for the second quarter of 2024, showing a slight increase in overall sales of 0.2% reaching $2.081 billion. The company raised its full-year guidance for organic sales growth and adjusted earnings per share (EPS), reflecting an optimistic outlook post-separation from 3M. However, challenges remain, including a decline in operating income margins and specific sectors, such as the Dental Solutions segment, experiencing losses. The CEO acknowledged the complexities of the transformation but emphasized a strong foundation for future growth.
Read more →SOLVConferences/Events
Solventum to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
Solventum to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
Read more →SOLVGeneral
U.S. News & World Report Expands Use of Solventum's Ambulatory Potentially Preventable Complications Grouping Software for Use in Its 2024-2025 Best Hospitals Rankings
U.S. News & World Report Expands Use of Solventum's Ambulatory Potentially Preventable Complications Grouping Software for Use in Its 2024-2025 Best Hospitals Rankings
Read more →SOLVGeneral
Solventum introduces denials prevention solution, an AI-powered tool, empowering health systems to help reduce write-offs and improve top line revenue
Solventum introduces denials prevention solution, an AI-powered tool, empowering health systems to help reduce write-offs and improve top line revenue
Read more →SOLVGeneral
Solventum Cautions Investors Regarding TRC Capital's "Mini-Tender Offer"
Solventum Cautions Investors Regarding TRC Capital's "Mini-Tender Offer"
Read more →SOLVGeneral
Solventum Reports First Quarter 2024 Financial Results and Capital Allocation Update Completed spin-off from 3M and began trading on
Solventum has reported its first-quarter financial results for 2024 following its recent spin-off from 3M. The company achieved sales of $2.016 billion, with a slight increase of 0.2% year-over-year. Despite this growth, the forecast for organic revenue is projected between -2% to 0%, raising concerns about future sales performance. Furthermore, Solventum has emphasized its focus on debt paydown and has decided against dividend payments or stock repurchases for the time being.
Read more →SOLVGeneral
Solventum Announces First Quarter 2024 Earnings Release Date and Upcoming Investor Events
Solventum Announces First Quarter 2024 Earnings Release Date and Upcoming Investor Events
Read more →SOLVGeneral
Solventum Names Shirley Edwards to Board of Directors
Solventum Names Shirley Edwards to Board of Directors
Read more →SOLVGeneral
Solventum Begins Trading on the New York Stock Exchange Formerly 3M Health Care Business, Solventum (NYSE SOLV) enables better, smarter, safer healthcare to improve lives
Solventum, formerly part of 3M, has officially begun trading on the New York Stock Exchange under the ticker SOLV following its spin-off. The company aims to deliver better healthcare solutions and has reported sales of $8.2 billion in 2023. CEO Bryan Hanson emphasized Solventum's commitment to innovation and long-term shareholder value, despite certain operational and market risks that could impact financial performance.
Read more →